260 related articles for article (PubMed ID: 30796038)
1. TET2 binding to enhancers facilitates transcription factor recruitment in hematopoietic cells.
Rasmussen KD; Berest I; Keβler S; Nishimura K; Simón-Carrasco L; Vassiliou GS; Pedersen MT; Christensen J; Zaugg JB; Helin K
Genome Res; 2019 Apr; 29(4):564-575. PubMed ID: 30796038
[TBL] [Abstract][Full Text] [Related]
2. Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis.
Rasmussen KD; Jia G; Johansen JV; Pedersen MT; Rapin N; Bagger FO; Porse BT; Bernard OA; Christensen J; Helin K
Genes Dev; 2015 May; 29(9):910-22. PubMed ID: 25886910
[TBL] [Abstract][Full Text] [Related]
3. TET2 coactivates gene expression through demethylation of enhancers.
Wang L; Ozark PA; Smith ER; Zhao Z; Marshall SA; Rendleman EJ; Piunti A; Ryan C; Whelan AL; Helmin KA; Morgan MA; Zou L; Singer BD; Shilatifard A
Sci Adv; 2018 Nov; 4(11):eaau6986. PubMed ID: 30417100
[TBL] [Abstract][Full Text] [Related]
4. DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia.
Rampal R; Alkalin A; Madzo J; Vasanthakumar A; Pronier E; Patel J; Li Y; Ahn J; Abdel-Wahab O; Shih A; Lu C; Ward PS; Tsai JJ; Hricik T; Tosello V; Tallman JE; Zhao X; Daniels D; Dai Q; Ciminio L; Aifantis I; He C; Fuks F; Tallman MS; Ferrando A; Nimer S; Paietta E; Thompson CB; Licht JD; Mason CE; Godley LA; Melnick A; Figueroa ME; Levine RL
Cell Rep; 2014 Dec; 9(5):1841-1855. PubMed ID: 25482556
[TBL] [Abstract][Full Text] [Related]
5. Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML.
Duy C; Teater M; Garrett-Bakelman FE; Lee TC; Meydan C; Glass JL; Li M; Hellmuth JC; Mohammad HP; Smitheman KN; Shih AH; Abdel-Wahab O; Tallman MS; Guzman ML; Muench D; Grimes HL; Roboz GJ; Kruger RG; Creasy CL; Paietta EM; Levine RL; Carroll M; Melnick AM
Cancer Discov; 2019 Jul; 9(7):872-889. PubMed ID: 31076479
[TBL] [Abstract][Full Text] [Related]
6. Activity of a heptad of transcription factors is associated with stem cell programs and clinical outcome in acute myeloid leukemia.
Diffner E; Beck D; Gudgin E; Thoms JA; Knezevic K; Pridans C; Foster S; Goode D; Lim WK; Boelen L; Metzeler KH; Micklem G; Bohlander SK; Buske C; Burnett A; Ottersbach K; Vassiliou GS; Olivier J; Wong JW; Göttgens B; Huntly BJ; Pimanda JE
Blood; 2013 Mar; 121(12):2289-300. PubMed ID: 23327922
[TBL] [Abstract][Full Text] [Related]
7. PU.1-Dependent Enhancer Inhibition Separates Tet2-Deficient Hematopoiesis from Malignant Transformation.
Aivalioti MM; Bartholdy BA; Pradhan K; Bhagat TD; Zintiridou A; Jeong JJ; Thiruthuvanathan VJ; Pujato M; Paranjpe A; Zhang C; Levine RL; Viny AD; Wickrema A; Verma A; Will B
Blood Cancer Discov; 2022 Sep; 3(5):444-467. PubMed ID: 35820129
[TBL] [Abstract][Full Text] [Related]
8. Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells.
Pan F; Wingo TS; Zhao Z; Gao R; Makishima H; Qu G; Lin L; Yu M; Ortega JR; Wang J; Nazha A; Chen L; Yao B; Liu C; Chen S; Weeks O; Ni H; Phillips BL; Huang S; Wang J; He C; Li GM; Radivoyevitch T; Aifantis I; Maciejewski JP; Yang FC; Jin P; Xu M
Nat Commun; 2017 Apr; 8():15102. PubMed ID: 28440315
[TBL] [Abstract][Full Text] [Related]
9. Clonal hematopoiesis related TET2 loss-of-function impedes IL1β-mediated epigenetic reprogramming in hematopoietic stem and progenitor cells.
McClatchy J; Strogantsev R; Wolfe E; Lin HY; Mohammadhosseini M; Davis BA; Eden C; Goldman D; Fleming WH; Conley P; Wu G; Cimmino L; Mohammed H; Agarwal A
Nat Commun; 2023 Dec; 14(1):8102. PubMed ID: 38062031
[TBL] [Abstract][Full Text] [Related]
10. TET2 Mutations Affect Non-CpG Island DNA Methylation at Enhancers and Transcription Factor-Binding Sites in Chronic Myelomonocytic Leukemia.
Yamazaki J; Jelinek J; Lu Y; Cesaroni M; Madzo J; Neumann F; He R; Taby R; Vasanthakumar A; Macrae T; Ostler KR; Kantarjian HM; Liang S; Estecio MR; Godley LA; Issa JP
Cancer Res; 2015 Jul; 75(14):2833-43. PubMed ID: 25972343
[TBL] [Abstract][Full Text] [Related]
11. p300 suppresses the transition of myelodysplastic syndromes to acute myeloid leukemia.
Man N; Mas G; Karl DL; Sun J; Liu F; Yang Q; Torres-Martin M; Itonaga H; Martinez C; Chen S; Xu Y; Duffort S; Hamard PJ; Chen C; Zucconi BE; Cimmino L; Yang FC; Xu M; Cole PA; Figueroa ME; Nimer SD
JCI Insight; 2021 Oct; 6(19):. PubMed ID: 34622806
[TBL] [Abstract][Full Text] [Related]
12. TET2 mutations are associated with hypermethylation at key regulatory enhancers in normal and malignant hematopoiesis.
Tulstrup M; Soerensen M; Hansen JW; Gillberg L; Needhamsen M; Kaastrup K; Helin K; Christensen K; Weischenfeldt J; Grønbæk K
Nat Commun; 2021 Oct; 12(1):6061. PubMed ID: 34663818
[TBL] [Abstract][Full Text] [Related]
13. Impact of constitutional TET2 haploinsufficiency on molecular and clinical phenotype in humans.
Kaasinen E; Kuismin O; Rajamäki K; Ristolainen H; Aavikko M; Kondelin J; Saarinen S; Berta DG; Katainen R; Hirvonen EAM; Karhu A; Taira A; Tanskanen T; Alkodsi A; Taipale M; Morgunova E; Franssila K; Lehtonen R; Mäkinen M; Aittomäki K; Palotie A; Kurki MI; Pietiläinen O; Hilpert M; Saarentaus E; Niinimäki J; Junttila J; Kaikkonen K; Vahteristo P; Skoda RC; Seppänen MRJ; Eklund KK; Taipale J; Kilpivaara O; Aaltonen LA
Nat Commun; 2019 Mar; 10(1):1252. PubMed ID: 30890702
[TBL] [Abstract][Full Text] [Related]
14. The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases.
Solary E; Bernard OA; Tefferi A; Fuks F; Vainchenker W
Leukemia; 2014 Mar; 28(3):485-96. PubMed ID: 24220273
[TBL] [Abstract][Full Text] [Related]
15. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation.
Moran-Crusio K; Reavie L; Shih A; Abdel-Wahab O; Ndiaye-Lobry D; Lobry C; Figueroa ME; Vasanthakumar A; Patel J; Zhao X; Perna F; Pandey S; Madzo J; Song C; Dai Q; He C; Ibrahim S; Beran M; Zavadil J; Nimer SD; Melnick A; Godley LA; Aifantis I; Levine RL
Cancer Cell; 2011 Jul; 20(1):11-24. PubMed ID: 21723200
[TBL] [Abstract][Full Text] [Related]
16. Histone lysine-specific demethylase 1 (LSD1) protein is involved in Sal-like protein 4 (SALL4)-mediated transcriptional repression in hematopoietic stem cells.
Liu L; Souto J; Liao W; Jiang Y; Li Y; Nishinakamura R; Huang S; Rosengart T; Yang VW; Schuster M; Ma Y; Yang J
J Biol Chem; 2013 Nov; 288(48):34719-28. PubMed ID: 24163373
[TBL] [Abstract][Full Text] [Related]
17. Impact of combinatorial dysfunctions of Tet2 and Ezh2 on the epigenome in the pathogenesis of myelodysplastic syndrome.
Hasegawa N; Oshima M; Sashida G; Matsui H; Koide S; Saraya A; Wang C; Muto T; Takane K; Kaneda A; Shimoda K; Nakaseko C; Yokote K; Iwama A
Leukemia; 2017 Apr; 31(4):861-871. PubMed ID: 27694924
[TBL] [Abstract][Full Text] [Related]
18. TET2 as an epigenetic master regulator for normal and malignant hematopoiesis.
Nakajima H; Kunimoto H
Cancer Sci; 2014 Sep; 105(9):1093-9. PubMed ID: 25040794
[TBL] [Abstract][Full Text] [Related]
19. Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression.
Cimmino L; Dolgalev I; Wang Y; Yoshimi A; Martin GH; Wang J; Ng V; Xia B; Witkowski MT; Mitchell-Flack M; Grillo I; Bakogianni S; Ndiaye-Lobry D; Martín MT; Guillamot M; Banh RS; Xu M; Figueroa ME; Dickins RA; Abdel-Wahab O; Park CY; Tsirigos A; Neel BG; Aifantis I
Cell; 2017 Sep; 170(6):1079-1095.e20. PubMed ID: 28823558
[TBL] [Abstract][Full Text] [Related]
20. Tet2 and Tet3 cooperate with B-lineage transcription factors to regulate DNA modification and chromatin accessibility.
Lio CW; Zhang J; González-Avalos E; Hogan PG; Chang X; Rao A
Elife; 2016 Nov; 5():. PubMed ID: 27869616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
